Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 128

1.

Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.

Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, Chang K.

J Child Adolesc Psychopharmacol. 2013 Oct;23(8):522-30. doi: 10.1089/cap.2012.0099. Epub 2013 Oct 10.

PMID:
24111982
[PubMed - indexed for MEDLINE]
2.

The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.

Amrami-Weizman A, Maayan R, Gil-Ad I, Pashinian A, Fuchs C, Kotler M, Poyurovsky M.

Psychopharmacology (Berl). 2013 Nov;230(1):23-7. doi: 10.1007/s00213-013-3199-1. Epub 2013 Jul 5.

PMID:
23828160
[PubMed - indexed for MEDLINE]
3.

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study.

Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC.

BMC Psychiatry. 2013 May 14;13:138. doi: 10.1186/1471-244X-13-138.

PMID:
23672672
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.

Katagiri H, Fujikoshi S, Suzuki T, Fujita K, Sugiyama N, Takahashi M, Gomez JC.

BMC Psychiatry. 2013 Jan 11;13:20. doi: 10.1186/1471-244X-13-20.

PMID:
23311957
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.

Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, Katagiri H, Gomez JC.

Br J Psychiatry. 2012 Nov;201(5):376-82. doi: 10.1192/bjp.bp.112.108357. Epub 2012 Aug 23.

PMID:
22918966
[PubMed - indexed for MEDLINE]
Free Article
6.

Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study.

Carey P, Suliman S, Ganesan K, Seedat S, Stein DJ.

Hum Psychopharmacol. 2012 Jul;27(4):386-91. doi: 10.1002/hup.2238. Epub 2012 Jun 22.

PMID:
22730105
[PubMed - indexed for MEDLINE]
7.

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.

Detke HC, Zhao F, Witte MM.

BMC Psychiatry. 2012 May 30;12:51. doi: 10.1186/1471-244X-12-51.

PMID:
22646847
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Does olanzapine inhibit the psychomimetic effects of Δ⁹-tetrahydrocannabinol?

Kleinloog D, Liem-Moolenaar M, Jacobs G, Klaassen E, de Kam M, Hijman R, van Gerven J.

J Psychopharmacol. 2012 Oct;26(10):1307-16. doi: 10.1177/0269881112446534. Epub 2012 May 16.

PMID:
22596206
[PubMed - indexed for MEDLINE]
9.

Pilot study of the efficacy of double-blind, placebo-controlled one-week olanzapine stabilization therapy in heterogeneous symptomatic bipolar disorder patients.

Srivastava S, Wang PW, Hill SJ, Childers ME, Keller KL, Ketter TA.

J Psychiatr Res. 2012 Jul;46(7):920-6. doi: 10.1016/j.jpsychires.2012.04.004. Epub 2012 May 10.

PMID:
22579071
[PubMed - indexed for MEDLINE]
10.

Open-label treatment with olanzapine for patients with borderline personality disorder.

Zanarini MC, Schulz SC, Detke H, Zhao F, Lin D, Pritchard M, Deberdt W, Fitzmaurice G, Corya S.

J Clin Psychopharmacol. 2012 Jun;32(3):398-402. doi: 10.1097/JCP.0b013e3182524293.

PMID:
22544004
[PubMed - indexed for MEDLINE]
11.

Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine.

Olsen BT, Ganocy SJ, Bitter SM, Findling RL, Case M, Chang K, Tohen M, DelBello MP.

Compr Psychiatry. 2012 Oct;53(7):1000-5. doi: 10.1016/j.comppsych.2012.03.010. Epub 2012 Apr 18.

PMID:
22520085
[PubMed - indexed for MEDLINE]
12.

Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression.

Weissman J, Flint A, Meyers B, Ghosh S, Mulsant B, Rothschild A, Whyte E; STOP-PD Study Group.

Psychiatry Res. 2012 May 30;197(3):221-6. Epub 2012 Mar 31.

PMID:
22464991
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.

McElroy SL, Winstanley E, Mori N, Martens B, McCoy J, Moeller D, Guerdjikova AI, Keck PE Jr.

J Clin Psychopharmacol. 2012 Apr;32(2):165-72. doi: 10.1097/JCP.0b013e3182488758.

PMID:
22367654
[PubMed - indexed for MEDLINE]
14.

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.

Witte MM, Case MG, Schuh KJ, Ascher-Svanum H.

Curr Med Res Opin. 2012 Mar;28(3):315-23. doi: 10.1185/03007995.2012.657300. Epub 2012 Jan 31.

PMID:
22236137
[PubMed - indexed for MEDLINE]
15.

Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study.

Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M.

J Affect Disord. 2012 Feb;136(3):476-84. doi: 10.1016/j.jad.2011.10.045. Epub 2011 Nov 30.

PMID:
22134043
[PubMed - indexed for MEDLINE]
16.

Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.

Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A.

Am J Psychiatry. 2011 Sep;168(9):957-67. doi: 10.1176/appi.ajp.2011.10060907. Epub 2011 Jun 15.

PMID:
21676992
[PubMed - indexed for MEDLINE]
17.

A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa.

Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, Saito E, Sunday S, Higdon C, Golden NH, Malhotra AK.

J Child Adolesc Psychopharmacol. 2011 Jun;21(3):207-12. doi: 10.1089/cap.2010.0139.

PMID:
21663423
[PubMed - indexed for MEDLINE]
18.

Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.

Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW.

Clin Schizophr Relat Psychoses. 2011 Apr;5(1):17-25. doi: 10.3371/CSRP.5.1.3.

PMID:
21459735
[PubMed - indexed for MEDLINE]
19.

Olanzapine versus placebo for out-patients with anorexia nervosa.

Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, Musante D, Wang Y.

Psychol Med. 2011 Oct;41(10):2177-82. doi: 10.1017/S0033291711000390. Epub 2011 Mar 22.

PMID:
21426603
[PubMed - indexed for MEDLINE]
20.

Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial.

Larsen KA, Kelly SE, Stern TA, Bode RH Jr, Price LL, Hunter DJ, Gulczynski D, Bierbaum BE, Sweeney GA, Hoikala KA, Cotter JJ, Potter AW.

Psychosomatics. 2010 Sep-Oct;51(5):409-18. doi: 10.1176/appi.psy.51.5.409.

PMID:
20833940
[PubMed - indexed for MEDLINE]
21.

A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania.

Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J.

J Clin Psychiatry. 2010 Oct;71(10):1336-43. doi: 10.4088/JCP.09m05114gre. Epub 2010 Apr 20.

PMID:
20441724
[PubMed - indexed for MEDLINE]
22.

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.

Narula PK, Rehan HS, Unni KE, Gupta N.

Schizophr Res. 2010 May;118(1-3):218-23. doi: 10.1016/j.schres.2010.02.001. Epub 2010 Mar 7.

PMID:
20207521
[PubMed - indexed for MEDLINE]
23.

Increased food intake and energy expenditure following administration of olanzapine to healthy men.

Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, Most MM, Fryburg DA.

Obesity (Silver Spring). 2010 Aug;18(8):1646-51. doi: 10.1038/oby.2010.6. Epub 2010 Feb 4.

PMID:
20134408
[PubMed - indexed for MEDLINE]
24.

Asenapine versus olanzapine in acute mania: a double-blind extension study.

McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J.

Bipolar Disord. 2009 Dec;11(8):815-26. doi: 10.1111/j.1399-5618.2009.00749.x. Epub 2009 Oct 14. Erratum in: Bipolar Disord. 2010 Feb;12(1):112.

PMID:
19832806
[PubMed - indexed for MEDLINE]
25.

Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.

Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA.

J Clin Psychiatry. 2009 Nov;70(11):1540-7. doi: 10.4088/JCP.08m04895yel. Epub 2009 Sep 22. Erratum in: J Clin Psychiatry. 2011 Aug;72(8):1157. J Clin Psychiatry. 2010 Jan;71(1):93.

PMID:
19778495
[PubMed - indexed for MEDLINE]
26.

A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study.

Karagianis J, Grossman L, Landry J, Reed VA, de Haan L, Maguire GA, Hoffmann VP, Milev R.

Schizophr Res. 2009 Aug;113(1):41-8. doi: 10.1016/j.schres.2009.05.024. Epub 2009 Jun 16. Erratum in: Schizophr Res. 2011 Dec;133(1-3):266.

PMID:
19535229
[PubMed - indexed for MEDLINE]
27.

Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine.

Salmasi FB, Jazayeri M, Ghaeli P, Hashemian F, Akhondzadeh S, Raisi F, Hosseini SH, Setareh MJ, Khavidaki SD.

J Clin Psychopharmacol. 2009 Apr;29(2):182-3. doi: 10.1097/JCP.0b013e31819a6aa2. No abstract available.

PMID:
19512983
[PubMed - indexed for MEDLINE]
28.

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC.

J Clin Psychopharmacol. 2009 Apr;29(2):165-9. doi: 10.1097/JCP.0b013e31819a8dbe.

PMID:
19512978
[PubMed - indexed for MEDLINE]
29.

Olanzapine in cocaine dependence: a double-blind, placebo-controlled trial.

Hamilton JD, Nguyen QX, Gerber RM, Rubio NB.

Am J Addict. 2009 Jan-Feb;18(1):48-52. doi: 10.1080/10550490802544318.

PMID:
19219665
[PubMed - indexed for MEDLINE]
30.

Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.

Baptista T, Rangel N, El Fakih Y, Uzcátegui E, Galeazzi T, Beaulieu S, Araujo de Baptista E.

Pharmacopsychiatry. 2009 Jan;42(1):14-9. doi: 10.1055/s-0028-1085438. Epub 2009 Jan 19.

PMID:
19153941
[PubMed - indexed for MEDLINE]
31.

An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects.

Roerig JL, Steffen KJ, Mitchell JE, Crosby RD, Gosnell BA.

Biol Psychiatry. 2009 Apr 1;65(7):607-13. doi: 10.1016/j.biopsych.2008.10.037. Epub 2008 Dec 21.

PMID:
19103435
[PubMed - indexed for MEDLINE]
32.

Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.

Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M.

J Am Acad Child Adolesc Psychiatry. 2009 Jan;48(1):60-70. doi: 10.1097/CHI.0b013e3181900404.

PMID:
19057413
[PubMed - indexed for MEDLINE]
33.

Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder.

Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL.

J Affect Disord. 2009 Jul;116(1-2):43-50. doi: 10.1016/j.jad.2008.11.003. Epub 2008 Dec 2.

PMID:
19054570
[PubMed - indexed for MEDLINE]
34.

Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.

Casey DE, Daniel DG, Tamminga C, Kane JM, Tran-Johnson T, Wozniak P, Abi-Saab W, Baker J, Redden L, Greco N, Saltarelli M.

Neuropsychopharmacology. 2009 Apr;34(5):1330-8. doi: 10.1038/npp.2008.209. Epub 2008 Dec 3.

PMID:
19052541
[PubMed - indexed for MEDLINE]
Free Article
35.

Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study.

Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, Tanaka Y, Lin D, Deberdt W, Corya S.

Br J Psychiatry. 2008 Dec;193(6):485-92. doi: 10.1192/bjp.bp.107.037903.

PMID:
19043153
[PubMed - indexed for MEDLINE]
Free Article
36.

Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.

Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, Shekhar A, Aaronson ST, Bardenstein L, Grecu-Gabos I, Tochilov V, Prelipceanu D, Oliff HS, Kryzhanovskaya L, Bowden C.

J Clin Psychiatry. 2008 Nov;69(11):1776-89. Epub 2008 Oct 7.

PMID:
19014751
[PubMed - indexed for MEDLINE]
37.

Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial.

Bissada H, Tasca GA, Barber AM, Bradwejn J.

Am J Psychiatry. 2008 Oct;165(10):1281-8. doi: 10.1176/appi.ajp.2008.07121900. Epub 2008 Jun 16.

PMID:
18558642
[PubMed - indexed for MEDLINE]
38.

Olanzapine reduces urge to smoke and nicotine withdrawal symptoms in community smokers.

Rohsenow DJ, Tidey JW, Miranda R, McGeary JE, Swift RM, Hutchison KE, Sirota AD, Monti PM.

Exp Clin Psychopharmacol. 2008 Jun;16(3):215-22. doi: 10.1037/1064-1297.16.3.215.

PMID:
18540781
[PubMed - indexed for MEDLINE]
39.

Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study.

Linehan MM, McDavid JD, Brown MZ, Sayrs JH, Gallop RJ.

J Clin Psychiatry. 2008 Jun;69(6):999-1005.

PMID:
18466045
[PubMed - indexed for MEDLINE]
40.

Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial.

Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, Eronen M, Räsänen P.

J Clin Psychiatry. 2008 May;69(5):706-11.

PMID:
18426261
[PubMed - indexed for MEDLINE]
41.

Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.

Baptista T, Uzcátegui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S, de Baptista EA.

Psychiatry Res. 2008 May 30;159(1-2):250-3. doi: 10.1016/j.psychres.2008.01.011. Epub 2008 Apr 18.

PMID:
18374423
[PubMed - indexed for MEDLINE]
42.

Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial.

McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr.

J Clin Psychiatry. 2008 Mar;69(3):433-40.

PMID:
18251624
[PubMed - indexed for MEDLINE]
43.

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.

Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH.

Am J Psychiatry. 2008 Mar;165(3):352-8. doi: 10.1176/appi.ajp.2007.07010079. Epub 2008 Feb 1.

PMID:
18245179
[PubMed - indexed for MEDLINE]
44.

Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes.

Tohen M, Bowden CL, Smulevich AB, Bergstrom R, Quinlan T, Osuntokun O, Wang WV, Oliff HS, Martenyi F, Kryzhanovskaya LA, Greil W.

Br J Psychiatry. 2008 Feb;192(2):135-43. doi: 10.1192/bjp.bp.107.041301.

PMID:
18245032
[PubMed - indexed for MEDLINE]
Free Article
45.

Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial.

Spettigue W, Buchholz A, Henderson K, Feder S, Moher D, Kourad K, Gaboury I, Norris M, Ledoux S.

BMC Pediatr. 2008 Jan 31;8:4. doi: 10.1186/1471-2431-8-4.

PMID:
18234120
[PubMed - indexed for MEDLINE]
Free PMC Article
46.

Olanzapine versus placebo in the treatment of adolescents with bipolar mania.

Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann RW, Biederman J.

Am J Psychiatry. 2007 Oct;164(10):1547-56.

PMID:
17898346
[PubMed - indexed for MEDLINE]
47.

Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation.

Egger C, Muehlbacher M, Schatz M, Nickel M.

J Clin Psychopharmacol. 2007 Oct;27(5):475-8.

PMID:
17873679
[PubMed - indexed for MEDLINE]
48.

Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.

Niufan G, Tohen M, Qiuqing A, Fude Y, Pope E, McElroy H, Ming L, Gaohua W, Xinbao Z, Huichun L, Liang S.

J Affect Disord. 2008 Jan;105(1-3):101-8. Epub 2007 May 24.

PMID:
17531327
[PubMed - indexed for MEDLINE]
49.

Olanzapine therapy in anorexia nervosa: psychobiological effects.

Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, Ramaciotti C, Bondi E, Mellado C, Borriello R, Monteleone P.

Int Clin Psychopharmacol. 2007 Jul;22(4):197-204.

PMID:
17519642
[PubMed - indexed for MEDLINE]
50.

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.

Baptista T, Rangel N, Fernández V, Carrizo E, El Fakih Y, Uzcátegui E, Galeazzi T, Gutiérrez MA, Servigna M, Dávila A, Uzcátegui M, Serrano A, Connell L, Beaulieu S, de Baptista EA.

Schizophr Res. 2007 Jul;93(1-3):99-108. Epub 2007 May 8.

PMID:
17490862
[PubMed - indexed for MEDLINE]
51.

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.

Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, Gil-Ad I.

Psychopharmacology (Berl). 2007 Jun;192(3):441-8. Epub 2007 Feb 20.

PMID:
17310385
[PubMed - indexed for MEDLINE]
52.

Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.

Assunção SS, Ruschel SI, Rosa Lde C, Campos JA, Alves MJ, Bracco OL, de Lima MS.

Rev Bras Psiquiatr. 2006 Dec;28(4):270-6. Erratum in: Rev Bras Psiquiatr. 2007 Mar;29(1):v.

PMID:
17242805
[PubMed - indexed for MEDLINE]
Free Article
53.

Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.

Strous RD, Stryjer R, Maayan R, Gal G, Viglin D, Katz E, Eisner D, Weizman A.

Psychoneuroendocrinology. 2007 Feb;32(2):96-105. Epub 2007 Jan 8.

PMID:
17208382
[PubMed - indexed for MEDLINE]
54.

Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers.

Giménez S, Clos S, Romero S, Grasa E, Morte A, Barbanoj MJ.

Psychopharmacology (Berl). 2007 Mar;190(4):507-16. Epub 2007 Jan 5.

PMID:
17205319
[PubMed - indexed for MEDLINE]
55.

A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.

Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, Novotny S.

J Child Adolesc Psychopharmacol. 2006 Oct;16(5):541-8.

PMID:
17069543
[PubMed - indexed for MEDLINE]
56.

The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.

Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S.

Acta Psychiatr Scand. 2006 Nov;114(5):319-27.

PMID:
17022791
[PubMed - indexed for MEDLINE]
57.

Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex.

Houston JP, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ.

J Clin Psychiatry. 2006 Aug;67(8):1246-52.

PMID:
16965203
[PubMed - indexed for MEDLINE]
58.

Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.

McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A.

Am J Psychiatry. 2006 May;163(5):790-9.

PMID:
16648318
[PubMed - indexed for MEDLINE]
59.

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.

Baptista T, Martínez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, Arapé Y, Martinez M, de Mendoza S, Teneud L, Hernández L.

Can J Psychiatry. 2006 Mar;51(3):192-6.

PMID:
16618011
[PubMed - indexed for MEDLINE]
60.

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.

Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL.

Am J Psychiatry. 2006 Feb;163(2):247-56.

PMID:
16449478
[PubMed - indexed for MEDLINE]
61.

Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.

Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, Meyers A, Kaiser C, Baker RW.

Int J Geriatr Psychiatry. 2005 Nov;20(11):1020-7.

PMID:
16250069
[PubMed - indexed for MEDLINE]
62.

Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study.

Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J.

Biol Psychiatry. 2006 Feb 1;59(3):211-5. Epub 2005 Sep 1.

PMID:
16139813
[PubMed - indexed for MEDLINE]
63.

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.

Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO.

Am J Psychiatry. 2005 Sep;162(9):1744-6.

PMID:
16135638
[PubMed - indexed for MEDLINE]
64.

Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.

Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, Lehman DL, Dossenbach M, Degenhardt EK, Breier A.

Am J Geriatr Psychiatry. 2005 Aug;13(8):722-30.

PMID:
16085789
[PubMed - indexed for MEDLINE]
65.

Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder.

Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E, Pérez V.

Am J Psychiatry. 2005 Jun;162(6):1221-4. Erratum in: Am J Psychiatry. 2008 Jun;165(6):777.

PMID:
15930077
[PubMed - indexed for MEDLINE]
66.

Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.

Keck PE Jr, Corya SA, Altshuler LL, Ketter TA, McElroy SL, Case M, Briggs SD, Tohen M.

J Clin Psychiatry. 2005 May;66(5):611-6.

PMID:
15889948
[PubMed - indexed for MEDLINE]
67.

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC.

Am J Psychiatry. 2005 May;162(5):954-62.

PMID:
15863798
[PubMed - indexed for MEDLINE]
68.

Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone?

Parker G, Brotchie H, Parker K.

Am J Psychiatry. 2005 Apr;162(4):796-8.

PMID:
15800157
[PubMed - indexed for MEDLINE]
69.

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.

Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M.

Biol Psychiatry. 2005 Mar 15;57(6):577-85.

PMID:
15780844
[PubMed - indexed for MEDLINE]
70.

Recovery and functional outcomes following olanzapine treatment for bipolar I mania.

Chengappa KN, Hennen J, Baldessarini RJ, Kupfer DJ, Yatham LN, Gershon S, Baker RW, Tohen M.

Bipolar Disord. 2005 Feb;7(1):68-76.

PMID:
15654934
[PubMed - indexed for MEDLINE]
71.

Weight gain during treatment of bipolar I patients with olanzapine.

Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ.

J Clin Psychiatry. 2004 Dec;65(12):1679-87.

PMID:
15641874
[PubMed - indexed for MEDLINE]
72.

Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data.

Vieta E, Calabrese JR, Hennen J, Colom F, Martínez-Arán A, Sánchez-Moreno J, Yatham LN, Tohen M, Baldessarini RJ.

J Clin Psychiatry. 2004 Oct;65(10):1420-8.

PMID:
15491248
[PubMed - indexed for MEDLINE]
73.

Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid.

Namjoshi MA, Risser R, Shi L, Tohen M, Breier A.

J Affect Disord. 2004 Sep;81(3):223-9.

PMID:
15337326
[PubMed - indexed for MEDLINE]
74.

Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.

Stephens RJ, Bassel C, Sandor P.

J Child Adolesc Psychopharmacol. 2004 Summer;14(2):255-66.

PMID:
15319022
[PubMed - indexed for MEDLINE]
75.

Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.

Chaichan W.

Psychiatry Clin Neurosci. 2004 Aug;58(4):364-8.

PMID:
15298648
[PubMed - indexed for MEDLINE]
76.

The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.

Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A.

Eur Neuropsychopharmacol. 2004 Aug;14(4):332-6.

PMID:
15163444
[PubMed - indexed for MEDLINE]
77.

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S.

J Clin Psychiatry. 2004 Apr;65(4):565-8.

PMID:
15119922
[PubMed - indexed for MEDLINE]
78.

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.

Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR.

Br J Psychiatry. 2004 Apr;184:337-45.

PMID:
15056579
[PubMed - indexed for MEDLINE]
Free Article
79.

Olanzapine attenuates cue-elicited craving for tobacco.

Hutchison KE, Rutter MC, Niaura R, Swift RM, Pickworth WB, Sobik L.

Psychopharmacology (Berl). 2004 Oct;175(4):407-13.

PMID:
15042276
[PubMed - indexed for MEDLINE]
80.

A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.

Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK.

Biol Psychiatry. 2004 Mar 1;55(5):553-5.

PMID:
15023585
[PubMed - indexed for MEDLINE]
81.

Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.

Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA.

Psychiatr Serv. 2004 Mar;55(3):290-4.

PMID:
15001730
[PubMed - indexed for MEDLINE]
82.

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.

De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A.

Int J Geriatr Psychiatry. 2004 Feb;19(2):115-26.

PMID:
14758577
[PubMed - indexed for MEDLINE]
83.

Olanzapine versus placebo in the treatment of borderline personality disorder.

Bogenschutz MP, George Nurnberg H.

J Clin Psychiatry. 2004 Jan;65(1):104-9.

PMID:
14744178
[PubMed - indexed for MEDLINE]
84.

Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.

Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor CC, Roth J, Battaglia J, Bitter I, Chouinard G, Morris PL, Breier A.

Can J Psychiatry. 2003 Dec;48(11):716-21.

PMID:
14733451
[PubMed - indexed for MEDLINE]
85.

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.

Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC.

Biol Psychiatry. 2004 Jan 15;55(2):165-71.

PMID:
14732596
[PubMed - indexed for MEDLINE]
86.

A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.

Beasley CM Jr, Sutton VK, Hamilton SH, Walker DJ, Dossenbach M, Taylor CC, Alaka KJ, Bykowski D, Tollefson GD; Olanzapine Relapse Prevention Study Group.

J Clin Psychopharmacol. 2003 Dec;23(6):582-94.

PMID:
14624189
[PubMed - indexed for MEDLINE]
87.

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.

Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A.

Arch Gen Psychiatry. 2003 Nov;60(11):1079-88. Erratum in: Arch Gen Psychiatry. 2004 Feb;61(2):176.

PMID:
14609883
[PubMed - indexed for MEDLINE]
88.

The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder.

Hirschfeld RM, Baker JD, Wozniak P, Tracy K, Sommerville KW.

J Clin Psychiatry. 2003 Jul;64(7):841-6.

PMID:
12934987
[PubMed - indexed for MEDLINE]
89.

Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B.

Hum Psychopharmacol. 2003 Aug;18(6):457-61.

PMID:
12923824
[PubMed - indexed for MEDLINE]
90.

Olanzapine versus placebo in acute mania: treatment responses in subgroups.

Baldessarini RJ, Hennen J, Wilson M, Calabrese J, Chengappa R, Keck PE Jr, McElroy SL, Sachs G, Vieta E, Welge JA, Yatham LN, Zarate CA Jr, Baker RW, Tohen M.

J Clin Psychopharmacol. 2003 Aug;23(4):370-6.

PMID:
12920413
[PubMed - indexed for MEDLINE]
91.

Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome.

Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH.

Biol Psychiatry. 2003 Aug 15;54(4):453-64. Erratum in: Biol Psychiatry. 2003 Aug 15;54(4):497.

PMID:
12915290
[PubMed - indexed for MEDLINE]
92.

A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.

Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris P, Breier A.

Clin Ther. 2003 May;25(5):1420-8.

PMID:
12867218
[PubMed - indexed for MEDLINE]
93.

Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.

Lindborg SR, Beasley CM, Alaka K, Taylor CC.

Psychiatry Res. 2003 Jul 15;119(1-2):113-23.

PMID:
12860365
[PubMed - indexed for MEDLINE]
94.

A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities.

Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF.

J Clin Psychiatry. 2003 Jun;64(6):726-30.

PMID:
12823090
[PubMed - indexed for MEDLINE]
95.

Calming versus sedative effects of intramuscular olanzapine in agitated patients.

Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P.

Am J Emerg Med. 2003 May;21(3):192-8.

PMID:
12811711
[PubMed - indexed for MEDLINE]
96.

Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania.

Chengappa KN, Baker RW, Shao L, Yatham LN, Tohen M, Gershon S, Kupfer DJ.

Bipolar Disord. 2003 Feb;5(1):1-5.

PMID:
12656931
[PubMed - indexed for MEDLINE]
97.

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.

Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH.

Schizophr Res. 2003 May 1;61(1):19-30.

PMID:
12648732
[PubMed - indexed for MEDLINE]
98.

The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.

McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A.

Schizophr Res. 2003 May 1;61(1):7-18.

PMID:
12648731
[PubMed - indexed for MEDLINE]
99.

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.

Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A.

Am J Psychiatry. 2003 Feb;160(2):297-302.

PMID:
12562576
[PubMed - indexed for MEDLINE]
100.

Efficacy of olanzapine in social anxiety disorder: a pilot study.

Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR.

J Psychopharmacol. 2002 Dec;16(4):365-8.

PMID:
12503837
[PubMed - indexed for MEDLINE]
101.

Olanzapine treatment for dopaminergic-induced hallucinations.

Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J.

Mov Disord. 2002 Sep;17(5):1031-5.

PMID:
12360554
[PubMed - indexed for MEDLINE]
102.

Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.

Stein MB, Kline NA, Matloff JL.

Am J Psychiatry. 2002 Oct;159(10):1777-9.

PMID:
12359687
[PubMed - indexed for MEDLINE]
103.

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.

Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH.

Biol Psychiatry. 2002 Sep 1;52(5):438-45.

PMID:
12242060
[PubMed - indexed for MEDLINE]
104.

Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial.

Namjoshi MA, Rajamannar G, Jacobs T, Sanger TM, Risser R, Tohen MF, Breier A, Keck PE Jr.

J Affect Disord. 2002 May;69(1-3):109-18.

PMID:
12103458
[PubMed - indexed for MEDLINE]
105.

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.

Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A.

Am J Psychiatry. 2002 Jun;159(6):1058-60.

PMID:
12042201
[PubMed - indexed for MEDLINE]
106.

A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.

Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P.

Arch Gen Psychiatry. 2002 May;59(5):441-8.

PMID:
11982448
[PubMed - indexed for MEDLINE]
107.

Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.

Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, Feldman PD, Mintzer JE, Beckett LM, Breier A.

Neuropsychopharmacology. 2002 Apr;26(4):494-504.

PMID:
11927174
[PubMed - indexed for MEDLINE]
Free Article
108.

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.

Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC.

Am J Psychiatry. 2002 Mar;159(3):480-2.

PMID:
11870017
[PubMed - indexed for MEDLINE]
109.

Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.

Cummings JL, Street J, Masterman D, Clark WS.

Dement Geriatr Cogn Disord. 2002;13(2):67-73.

PMID:
11844887
[PubMed - indexed for MEDLINE]
110.

Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.

Zanarini MC, Frankenburg FR.

J Clin Psychiatry. 2001 Nov;62(11):849-54.

PMID:
11775043
[PubMed - indexed for MEDLINE]
111.

Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.

Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA.

J Am Acad Child Adolesc Psychiatry. 2001 Aug;40(8):887-94.

PMID:
11501687
[PubMed - indexed for MEDLINE]
112.

A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.

Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, Breier A.

J Clin Psychopharmacol. 2001 Aug;21(4):389-97.

PMID:
11476123
[PubMed - indexed for MEDLINE]
113.

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.

Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, Saunders JC, Krueger J, Bradley P, San L, Bernardo M, Reinstein M, Breier A.

Am J Psychiatry. 2001 Jul;158(7):1149-51.

PMID:
11431240
[PubMed - indexed for MEDLINE]
114.

Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.

Czekalla J, Beasley CM Jr, Dellva MA, Berg PH, Grundy S.

J Clin Psychiatry. 2001 Mar;62(3):191-8.

PMID:
11305706
[PubMed - indexed for MEDLINE]
115.

The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.

Clark WS, Street JS, Feldman PD, Breier A.

J Clin Psychiatry. 2001 Jan;62(1):34-40.

PMID:
11235926
[PubMed - indexed for MEDLINE]
116.

The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.

Jones B, Taylor CC, Meehan K.

J Clin Psychiatry. 2001;62 Suppl 2:22-4.

PMID:
11232747
[PubMed - indexed for MEDLINE]
117.

Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.

Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL.

J Clin Psychiatry. 2000 Nov;61(11):833-40.

PMID:
11105736
[PubMed - indexed for MEDLINE]
118.

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.

Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A.

Arch Gen Psychiatry. 2000 Oct;57(10):968-76.

PMID:
11015815
[PubMed - indexed for MEDLINE]
119.

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A.

Arch Gen Psychiatry. 2000 Sep;57(9):841-9. Erratum in: Arch Gen Psychiatry 2002 Jan;59(1):91.

PMID:
10986547
[PubMed - indexed for MEDLINE]
120.

Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.

Tollefson GD, Dellva MA, Mattler CA, Kane JM, Wirshing DA, Kinon BJ.

J Clin Psychopharmacol. 1999 Oct;19(5):435-43.

PMID:
10505585
[PubMed - indexed for MEDLINE]
121.

Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.

Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V.

Am J Psychiatry. 1999 May;156(5):702-9.

PMID:
10327902
[PubMed - indexed for MEDLINE]
122.

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

Tollefson GD, Sanger TM, Beasley CM, Tran PV.

Biol Psychiatry. 1998 Jun 1;43(11):803-10.

PMID:
9611669
[PubMed - indexed for MEDLINE]
123.

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr.

Neuropsychopharmacology. 1998 Jan;18(1):41-9.

PMID:
9408917
[PubMed - indexed for MEDLINE]
Free Article
124.

Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.

Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr.

Psychiatr Serv. 1997 Dec;48(12):1571-7.

PMID:
9406266
[PubMed - indexed for MEDLINE]
125.

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.

Crawford AM, Beasley CM Jr, Tollefson GD.

Schizophr Res. 1997 Jul 25;26(1):41-54.

PMID:
9376336
[PubMed - indexed for MEDLINE]
126.

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.

Tollefson GD, Sanger TM.

Am J Psychiatry. 1997 Apr;154(4):466-74.

PMID:
9090332
[PubMed - indexed for MEDLINE]
127.

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S.

Neuropsychopharmacology. 1996 Feb;14(2):111-23.

PMID:
8822534
[PubMed - indexed for MEDLINE]
Free Article
128.

Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.

Baker RW, Ames D, Umbricht DS, Chengappa KN, Schooler NR.

Psychopharmacol Bull. 1996;32(1):89-93.

PMID:
8927681
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk